Global gene profiling has uncovered previously unrecognized subtype of human breast cancer, including the so-called “triple-negative” or “basal-like” tumors characterized by estrogen/progesterone receptor negativity, lack of HER2 amplification and high frequency of p53 mutation [1–6]. The gene discussed is ERBB2; the disease is breast cancer.